Literature DB >> 15388424

In vitro activities of 2,4-diaminoquinazoline and 2,4-diaminopteridine derivatives against Plasmodium falciparum.

Sheila Ommeh1, Eunice Nduati, Eddy Mberu, Gilbert Kokwaro, Kevin Marsh, Andre Rosowsky, Alexis Nzila.   

Abstract

The activities of 28 6-substituted 2,4-diaminoquinazolines, 2,4-diamino-5,6,7,8-tetrahydroquinazolines, and 2,4-diaminopteridines against Plasmodium falciparum were tested. The 50% inhibitory concentrations (IC(50)s) of six compounds were <50 nM, and the most potent compound was 2,4-diamino-5-chloro-6-[N-(2,5-dimethoxybenzyl)amino]quinazoline (compound 1), with an IC(50) of 9 nM. The activity of compound 1 was potentiated by the dihydropteroate synthase inhibitor dapsone, an indication that these compounds are inhibitors of dihydrofolate reductase. Further studies are warranted to assess the therapeutic potential of this combination in vivo.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15388424      PMCID: PMC521929          DOI: 10.1128/AAC.48.10.3711-3714.2004

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  15 in total

1.  The development of Lapdap, an affordable new treatment for malaria.

Authors:  Trudie Lang; Brian Greenwood
Journal:  Lancet Infect Dis       Date:  2003-03       Impact factor: 25.071

Review 2.  Pyrimethamine-sulfadoxine resistance in Plasmodium falciparum: what next?

Authors:  C H Sibley; J E Hyde; P F Sims; C V Plowe; J G Kublin; E K Mberu; A F Cowman; P A Winstanley; W M Watkins; A M Nzila
Journal:  Trends Parasitol       Date:  2001-12

3.  Antifolate-resistant mutants of Plasmodium falciparum dihydrofolate reductase.

Authors:  W Sirawaraporn; T Sathitkul; R Sirawaraporn; Y Yuthavong; D V Santi
Journal:  Proc Natl Acad Sci U S A       Date:  1997-02-18       Impact factor: 11.205

4.  Can pretreatment screening for dhps and dhfr point mutations in Plasmodium falciparum infections be used to predict sulfadoxine-pyrimethamine treatment failure?

Authors:  S A Omar; I S Adagu; D C Warhurst
Journal:  Trans R Soc Trop Med Hyg       Date:  2001 May-Jun       Impact factor: 2.184

5.  Amodiaquine, sulfadoxine/pyrimethamine, and combination therapy for treatment of uncomplicated falciparum malaria in Kampala, Uganda: a randomised trial.

Authors:  S G Staedke; M R Kamya; G Dorsey; A Gasasira; G Ndeezi; E D Charlebois; P J Rosenthal
Journal:  Lancet       Date:  2001-08-04       Impact factor: 79.321

6.  Towards an understanding of the mechanism of pyrimethamine-sulfadoxine resistance in Plasmodium falciparum: genotyping of dihydrofolate reductase and dihydropteroate synthase of Kenyan parasites.

Authors:  A M Nzila; E K Mberu; J Sulo; H Dayo; P A Winstanley; C H Sibley; W M Watkins
Journal:  Antimicrob Agents Chemother       Date:  2000-04       Impact factor: 5.191

7.  Chlorproguanil-dapsone for treatment of drug-resistant falciparum malaria in Tanzania.

Authors:  T Mutabingwa; A Nzila; E Mberu; E Nduati; P Winstanley; E Hills; W Watkins
Journal:  Lancet       Date:  2001-10-13       Impact factor: 79.321

8.  Chlorproguanil-dapsone (LAPDAP) for uncomplicated falciparum malaria.

Authors:  P Winstanley
Journal:  Trop Med Int Health       Date:  2001-11       Impact factor: 2.622

9.  Clinical efficacy of chloroquine or sulfadoxine-pyrimethamine in children under five from south-western Uganda with uncomplicated falciparum malaria.

Authors:  D Legros; K Johnson; P Houpikian; M Makanga; J K Kabakyenga; A O Talisuna; W R J Taylor
Journal:  Trans R Soc Trop Med Hyg       Date:  2002 Mar-Apr       Impact factor: 2.184

10.  The safety and efficacy of sulfadoxine-pyrimethamine, amodiaquine, and their combination in the treatment of uncomplicated Plasmodium falciparum malaria.

Authors:  David Schellenberg; Elizeus Kahigwa; Chris Drakeley; Athumani Malende; John Wigayi; Chris Msokame; John J Aponte; Marcel Tanner; Hassan Mshinda; Clara Menendez; Pedro L Alonso
Journal:  Am J Trop Med Hyg       Date:  2002-07       Impact factor: 2.345

View more
  7 in total

1.  Preclinical evaluation of the antifolate QN254, 5-chloro- N'6'-(2,5-dimethoxy-benzyl)-quinazoline-2,4,6-triamine, as an antimalarial drug candidate.

Authors:  Alexis Nzila; Matthias Rottmann; Penchit Chitnumsub; Stevens M Kiara; Sumalee Kamchonwongpaisan; Cherdsak Maneeruttanarungroj; Supannee Taweechai; Bryan K S Yeung; Anne Goh; Suresh B Lakshminarayana; Bin Zou; Josephine Wong; Ngai Ling Ma; Margaret Weaver; Thomas H Keller; Veronique Dartois; Sergio Wittlin; Reto Brun; Yongyuth Yuthavong; Thierry T Diagana
Journal:  Antimicrob Agents Chemother       Date:  2010-03-29       Impact factor: 5.191

Review 2.  Comparative folate metabolism in humans and malaria parasites (part I): pointers for malaria treatment from cancer chemotherapy.

Authors:  Alexis Nzila; Steve A Ward; Kevin Marsh; Paul F G Sims; John E Hyde
Journal:  Trends Parasitol       Date:  2005-06

3.  In vitro chemosensitization of Plasmodium falciparum to antimalarials by verapamil and probenecid.

Authors:  Victor Masseno; Steven Muriithi; Alexis Nzila
Journal:  Antimicrob Agents Chemother       Date:  2009-04-13       Impact factor: 5.191

4.  Binding modes of 2,4-diaminoquinazoline and 2,4-diaminopteridine analogs to P. falciparum dihydrofolate reductase enzyme: Molecular docking studies.

Authors:  L Adane; P V Bharatam
Journal:  Indian J Pharm Sci       Date:  2010-05       Impact factor: 0.975

5.  Activation of 2,4-Diaminoquinazoline in Mycobacterium tuberculosis by Rv3161c, a Putative Dioxygenase.

Authors:  Eduard Melief; Shilah A Bonnett; Edison S Zuniga; Tanya Parish
Journal:  Antimicrob Agents Chemother       Date:  2018-12-21       Impact factor: 5.191

6.  Identification of Small Molecule Inhibitors of the Pathogen Box against Vibrio cholerae.

Authors:  Haeun Kim; Brianne J Burkinshaw; Linh G Lam; Kevin Manera; Tao G Dong
Journal:  Microbiol Spectr       Date:  2021-12-22

7.  Prediction of the P. falciparum target space relevant to malaria drug discovery.

Authors:  Andreas Spitzmüller; Jordi Mestres
Journal:  PLoS Comput Biol       Date:  2013-10-17       Impact factor: 4.475

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.